Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alphamab Oncology
After Novartis, US firm Coherus leaps into the China immuno-oncology fray by licensing rights to innovative drugs from Shanghai's Junshi.
As the China immuno-oncology sector becomes increasingly crowded, CStone teams up with an innovative US business partner to go global.
The latest big pharma vote of confidence in both the China market and R&D capabilities comes amid continuing standoffs with the US over a flurry of issues including the coronavirus, national security and trade, but as the pandemic seemingly recedes in China.
Sinovac's candidate is a more conventional inactivated vaccine, but is keeping pace with more modern approaches taken by Moderna and CanSino.
- Large Molecule
- Other Names / Subsidiaries
- Alphamab Biopharmaceuticals Co., Ltd.
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
- Suzhou Alphamab Co., Ltd.